Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress [Yahoo! Finance]
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock, down previously from $10.00.